Comparative Pharmacology
Head-to-head clinical analysis: TARGRETIN versus TRETINOIN MICROSPHERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TARGRETIN versus TRETINOIN MICROSPHERE.
TARGRETIN vs TRETINOIN MICROSPHERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective retinoid X receptor (RXR) agonist that modulates gene expression involved in cell differentiation, proliferation, and apoptosis.
Tretinoin microsphere is a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ), modulating gene expression involved in cell proliferation, differentiation, and inflammation. It normalizes follicular keratinization, reduces microcomedone formation, and increases epidermal turnover.
300 mg/m2 orally once daily.
Apply a pea-sized amount (approximately 0.5 g) topically once daily at bedtime to dry skin.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 3–10 hours) for the parent drug. The active metabolite (bexarotene glucuronide) has a half-life of about 9 hours. Clinically, steady state is reached within 3–5 days.
Terminal elimination half-life approximately 0.5–2 hours in terminal phase; longer terminal phase (10–20 hours) observed for 13-cis-retinoic acid metabolite.
Primarily metabolized in the liver via CYP3A4; elimination is mainly through hepatobiliary excretion into feces. Renal excretion is minimal (<3% as unchanged drug).
Primarily hepatic metabolism via CYP450 isoforms to polar metabolites; renal excretion accounts for <1% unchanged; biliary/fecal elimination of metabolites is significant (approximately 30-60%).
Category C
Category D/X
Retinoid
Retinoid